Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis

Inclusion Criteria: * Diagnosed with AK of the face or scalp * Has clinically typical, visible, and discrete AK lesions * Considered as a potential candidate for tirbanibulin (Klisyri®) treatment to manage their AK * Willing to avoid excessive sun or ultraviolet (UV) exposure, and/or use relevant sunscreen protection and protective clothing during the study duration * Able to read and write English * Provide consent to participate in the study * Willing to comply with all study procedures and be available for the duration of the study Exclusion Criteria: * Participants with any dermatological condition of the face or scalp that could interfere with the clinical evaluations. * Hypertrophic AK lesions, open wounds or suspected skin cancers within close proximity of the treatment area. * Anticipated need for in-patient hospitalization or in-patient surgery within the next 2 months. * Participants unable to comply with the requirements of the study or participants who in the opinion of the study physician should not participate in the study. * Participants for whom medical chart is inaccessible to physicians to complete baseline data collection.